Loading...
Asymchem Laboratories (Tianjin) Co., Ltd.
6821.HK•HKSE
Healthcare
Biotechnology
HK$74.40
HK$2.90(4.06%)
Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK) Financial Performance & Statements
Review Asymchem Laboratories (Tianjin) Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-25.82%
↓ 25.82%
Operating Income Growth
-58.04%
↓ 58.04%
Net Income Growth
-58.17%
↓ 58.17%
Operating Cash Flow Growth
-64.66%
↓ 64.66%
Operating Margin
19.22%
↑ 19.22%
Gross Margin
42.13%
↑ 42.13%
Net Profit Margin
16.71%
↑ 16.71%
ROE
5.93%
↑ 5.93%
ROIC
6.39%
↑ 6.39%
Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Asymchem Laboratories (Tianjin) Co., Ltd. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.66B | $1.44B | $1.28B | $1.36B |
| Cost of Revenue | $1.01B | $774.59M | $800.97M | $790.60M |
| Gross Profit | $653.47M | $668.35M | $480.93M | $568.18M |
| Gross Profit Ratio | $0.39 | $0.46 | $0.38 | $0.42 |
| R&D Expenses | $130.35M | $155.45M | $153.23M | $169.44M |
| SG&A Expenses | -$370.64M | $536.77M | $217.12M | $215.70M |
| Operating Expenses | $336.27M | $439.82M | $379.25M | $385.14M |
| Total Costs & Expenses | $1.35B | $1.21B | $1.18B | $1.18B |
| Interest Income | $43.02M | $54.87M | $183.10M | $62.40M |
| Interest Expense | $5.81M | $1.16M | $1.96M | $572586.00 |
| Depreciation & Amortization | $0.00 | -$12.38M | $127.16M | $105.52M |
| EBITDA | $319.04M | $227.67M | $372.24M | $422.73M |
| EBITDA Ratio | $0.19 | $0.16 | $0.29 | $0.31 |
| Operating Income | $317.21M | $240.05M | $101.68M | $183.04M |
| Operating Income Ratio | $0.19 | $0.17 | $0.08 | $0.13 |
| Other Income/Expenses (Net) | -$3.98M | -$10.02M | -$256314.00 | -$25011.00 |
| Income Before Tax | $313.23M | $230.03M | $243.12M | $294.99M |
| Income Before Tax Ratio | $0.19 | $0.16 | $0.19 | $0.22 |
| Income Tax Expense | $77.65M | $18.74M | $25.10M | $15.13M |
| Net Income | $238.62M | $211.19M | $217.16M | $281.97M |
| Net Income Ratio | $0.14 | $0.15 | $0.17 | $0.21 |
| EPS | $0.68 | $0.60 | $0.64 | $0.76 |
| Diluted EPS | $0.68 | $0.60 | $0.64 | $0.76 |
| Weighted Avg Shares Outstanding | $352.77M | $354.88M | $341.005M | $369.47M |
| Weighted Avg Shares Outstanding (Diluted) | $352.77M | $354.88M | $341.005M | $369.47M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan